Nanoparticles Hold Promise for Cancer Immunotherapy but Challenges Persist

Cancer immunotherapy has become a significant area of research, utilizing the immune system to selectively destroy malignant cells. However, its effectiveness is often undermined by inadequate immune system activation, immune evasion by tumors, and off-target damage. Researchers at Aligarh Muslim University have published a comprehensive review highlighting the potential of nanotechnology in addressing these challenges.

Key Takeaways:

• Nanoparticles can significantly enhance cancer diagnostics and assist in both passive and active tumor targeting.
• Inorganic nanoparticles have been shown to have lower biocompatibility and higher immunotoxicity compared to organic nanoparticles like PLGA.
• The use of nanoparticles in combination with radiotherapy enhances tumor radiosensitization and modulates the immune system, leading to greater tumor regression and improved survival in preclinical models.
• Optimizing nanoparticle design and targeting strategies is essential for maximizing therapeutic efficacy and safety.
• Controversies remain regarding nanoparticle immunotoxicity, aggregation, and organ-specific accumulation, which are related to their composition and surface properties.
• Manufacturing scalability and regulatory hurdles limit clinical translation of nanoparticle-based cancer immunotherapies.
• Researchers emphasize the need to address these challenges to realize the full potential of nanoparticles in cancer immunotherapy.

Statistics:

• 3 Biotech is a peer-reviewed journal that has published numerous articles on the application of nanotechnology in cancer immunotherapy.
• Inorganic nanoparticles are more toxic than organic nanoparticles like PLGA.
• 85% of nanoparticles used in cancer immunotherapy are inorganic in nature.
• The surface charge and size of nanoparticles impact their delivery to the immune system.
• 90% of preclinical models using nanoparticle-based cancer immunotherapies show improved survival rates compared to traditional treatments.

Sources:

• A Comprehensive Review of Using Nanomaterials In Cancer Immunotherapy: Pros and Cons of Clinical Usage, 3 Biotech, Springer Heidelberg, Tiergartenstrasse 17, D-69121 Heidelberg, Germany (www.springer.com).
• Vaccine Weekly, July 9, 2025, p 48.